Annotation: The use of psychotropic medications in children: An American view

Journal of Child Psychology and Psychiatry and Allied Disciplines

Volumn 44, Issue 2, 2003, Pages 159-168

  Wolraich, Mark L ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Children's mental disorders; Psychopharmacologic treatment; Psychotropic medications

Indexed keywords

ALCOHOL; AMITRIPTYLINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSPIRONE; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; CLOMIPRAMINE; DESIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LITHIUM SALT; METHYLPHENIDATE; MOOD STABILIZER; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PEMOLINE; PIMOZIDE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIOTIXENE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGGRESSION; AGITATION; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; APPETITE DISORDER; ATAXIA; ATTENTION DEFICIT DISORDER; AUTISM; BLOOD DYSCRASIA; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DYSPHORIA; ENURESIS; EUPHORIA; FOLLOW UP; GILLES DE LA TOURETTE SYNDROME; GOITER; HAIR LOSS; HEADACHE; HEART ARRHYTHMIA; HEART DISEASE; HEPATITIS; HUMAN; HYPERACTIVITY; HYPERTHYROIDISM; IMPULSIVENESS; LETHAL DOSE; LIVER FAILURE; LIVER TOXICITY; MENTAL DEFICIENCY; MENTAL DISEASE; MOOD DISORDER; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; PANCREATITIS; POLYURIA; PRESCRIPTION; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY; RELAPSE; REVIEW; SEDATION; SHORT COURSE THERAPY; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STOMACH PAIN; THIRST; THROMBOCYTOPENIA; TIC; TREMOR; VERTIGO; VISUAL DISORDER; WATER INTOXICATION; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; ARTICLE; CHILD PSYCHIATRY; CLINICAL PRACTICE; META ANALYSIS; PRESCHOOL CHILD; PRIMARY HEALTH CARE; TREATMENT OUTCOME; UNITED STATES;

ANXIETY DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD PSYCHIATRY; CHILD, PRESCHOOL; DEPRESSIVE DISORDER; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; PSYCHOTROPIC DRUGS; TREATMENT OUTCOME; UNITED STATES;

EID: 0041632272     PISSN: 00219630     EISSN: None     Source Type: Journal    
DOI: 10.1111/1469-7610.00110     Document Type: Review

References (100)

1. Aman, M.G., Teehan, C.J., White, A.J., Turbott, S.H., & Vaithianathan, C. (1989). Haloperidol treatment with chronically medicated residents: Dose effects on clinical behavior and reinforcement contingencies. American Journal of Mental Retardation, 93, 452-460.
2. American Academy of Pediatrics, Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement (2000). Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics, 105, 1158-1170.
3. American Academy of Pediatrics, Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement (2001). Clinical practice guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics, 108, 1033-1044.
4. Anderson, L.T., Campbell, M., Adams, P., Small, A.M., Perry, R., & Shell, J. (1989). The effects of haloperidol on discrimination learning and behavior symptoms in autistic children. Journal of Autism and Developmental Disorders, 19, 227-239.
5. Anderson, L.T., Campbell, M., Grega, D.M., Perry, R., Small, A.M., & Green, W.H. (1984). Haloperidol in infantile autism: Effects on learning and behavioral symptoms. American Journal of Psychiatry, 141, 1195-1202.
6. Angier, N. (1994). The debilitating malady called boyhood. New York Times, Section 4, pp. 1, 4.
7. Barkley, R.A., McMurray, M.B., Edelbrock, C.S., & Robbins, K. (1990). Side effects of methylphenidate in children with attention deficit hyperactivity disorder: A systemic placebo-controlled evaluation. Pediatrics, 86, 184-192.
8. Berkovitch, M., Pope, E., Phillips, J., & Koren, G. (1995). Pemoline-associated fulminate liver failure: Testing the evidence for causation. Clinical Pharmacologic Therapy, 57, 696-698.
9. Bernstein, G.A., Garfinkel, B.D., & Borchardt, C.M. (1990). Comparative studies of pharmacotherapy for school refusal. Journal of the American Academy of Child and Adolescent Psychiatry, 29, 773-781.
10. Bradley, C. (1937). The behavior of children receiving benzedrine. American Journal of Psychiatry, 94, 577-585.
11. Bradley, C., & Bowen, C. (1940). School performance of children receiving amphetamine (benzedrine) sulfate. American Journal of Orthopsychiatry, 10, 782-788.
12. Bruun, R. (1988). Subtle and under recognized side effects of neuroleptic treatment in children with Tourette's disorder. American Journal of Psychiatry, 145, 621-624.
13. Bruun, R., & Budman, C.L. (1996). Neuroleptic-induced behavior disorders in patients with Tourette's syndrome. In M. Richardson & G. Haugland (Eds.), Use of Neuroleptics in Children (pp. 185-198). Washington, DC: American Psychiatric Press.
14. Bussing, R., Zima, B.T., & Belin, T.R. (1998). Differential access to care for children with ADHD in special education programs. Psychiatric Services, 9, 1226-1229.
15. Campbell, M., Anderson, L.T., Meier, M., Cohen, I.L., Small, A.M., Samit, C., & Sachar, E.J. (1978). A comparison of haloperidol, behavior therapy and their interaction in autistic children. Journal of the American Academy of Child Psychiatry, 17, 640-655.
16. Campbell, M., Fish, B., Shapiro, T., & Floyd, A. (1970). Thiothixene in young disturbed children: A pilot study. Archives of General Psychiatry, 23, 70-72.
17. Campbell, M., Small, A.M., Green, W.H., Jennings, S.J., Perry, R., Bennett, W.G., & Anderson, L. (1984). Behavioral efficacy of haloperidol and lithium carbonate. Archives of General Psychiatry, 41, 650-656.
18. Cantwell, D.P. (1996). Attention deficit disorder: A review of the past 10 years. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 978-987.
19. Cohen, I.L., Campbell, M., Posner, D., Small, A.M., Triebel, D., & Anderson, L.T. (1980). Behavioral effects of haloperidol in young autistic children: An objective analysis using a within-subjects reversal design. Journal of the American Academy of Child Psychiatry, 19, 665-677.
20. Copeland, L., Wolraich, M., Lindgren, S., Milich, R., & Woolson, R. (1987). Pediatricians' reported practices in the assessment and treatment of attention deficit disorders. Journal of Developmental and Behavioral Pediatrics, 8, 191-196.
21. De Veaugh-Geiss, J., Moroz, G., Biederman, J., Cantwell, D., Fontaine, R., Greist, J.H., Reichler, R., Katz, R., & Landau, P. (1992). Clomipramine hydrochloride in childhood and adolescent obsessive compulsive disorder: A multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 45-49.
22. DeVane, C.L. (1994). Pharmacogenetics and drug metabolism of newer antidepressant agents. Journal of Clinical Psychiatry, 55(Suppl.), 38-47.
23. Diller, L.H. (1996). The run of Ritalin: Attention deficit disorder and stimulant treatment in the 1990s. Hastings Center Report, 26, 12-18.
24. Drug Enforcement Administration (1995). Yearly Aggregate Production Quotas. Washington, DC, Drug Enforcement Administration Office of Public Affairs.
25. Dulcan, M. (1997). Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 36(Suppl.), 85S-121S.
26. Dupaul, G.J., & Barkley, R.A. (1990). Medication therapy. In R.A. Barkley (Ed.), Attention Deficit Hyperactivity Disorder - A Handbook for Diagnosis and Treatment (pp. 573-612). New York: The Guilford Press.
27. Emslie, G.J., Rush, A.J., Weinberg, W.A., Kowatch, R.A., Hughes, C.W., Carmody, T., & Rintelmann, J. (1997). A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry, 54, 1031-1037.
28. Ernst, M., Magee, H.J., Gonzalez, N.M., Locascio, J.J., Rosenberg, C.R., & Campbell, M. (1992). Pimozide in autistic children. Psychopharmacological Bulletin, 28, 187-191.
29. Flament, M.F., Rapoport, J.L., Berg, C.J., Sceery, W., Kitts, C., Mellstrom, B., & Linnoila, M. (1985). Clomipramine treatment of childhood obsessive-compulsive disorder. Archives of General Psychiatry, 42, 977-983.
30. Foote, S.M., & Etheredge, L. (2000). Increasing use of new prescription drugs: A case study. Health Affairs, 19, 165-170.
31. Fritz, G.K., & Bergman, A.S. (1985). Child psychiatrists seen through pediatricians' eyes: Results of a national study. Journal of the American Academy of Child Psychiatry, 24, 81-86.
32. Garfinkel, B.D., Wender, P.H., Sloman, L., & O'Neill, I. (1983). Tricyclic antidepressants and methylphenidate treatment of attention deficit disorder in children and adolescents. Journal of Child and Adolescent Psychiatry, 22, 343-348.
33. Geller, B., Cooper, T.B., Sun, K., Zimmerman, B., Frazier, J., Williams, M., & Heath, J. (1998). Double-blind and placebo controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 171-178.
34. Geller, B., Reising, D., Leonard, H.L., Riddle, M.A., & Walsh, B.T. (1999). Critical review of tricyclic anti-depressant use in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 513-516.
35. Gittelman-Klein, R., Klein, D.F., Katz, S., Saraf, K., & Pollack, E. (1976). Comparative effects of methylphenidate and thioridazine in hyperkinetic children, I: Clinical results. Archives of General Psychiatry, 33, 1217-1231.
36. Gordon, C.T., State, R.C., Nelson, J.E., Hamburger, S.D., & Rapoport, J.L. (1993). A double-blind comparison of clomipramine, desipramine and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50, 441-447.
37. Graae, F., Milner, J., Rizzotto, L., & Klein, R.G. (1994). Clonazepam in childhood anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 372-376.
38. Greenhill, L.L., Halperin, J.M., & Abikoff, H. (1999). Stimulant medications. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 503-512.
39. Hechtman, L. (1985). Adolescent outcome of hyperactive children treated with stimulants in childhood: A review. Psychopharmacology Bulletin, 21, 178-191.
40. Hennes, H., Wagner, V., Bonadio, W.A., et al. (1990). Successful clonazepam treatment of adolescents with panic disorder. Annuals of Emergency Medicine, 19, 95-98.
41. International Narcotics Control Board. (1994). Report of the International Narcotics Control Board for 1994. Vienna: United Nations.
42. Jensen, P. (1998). Behavioral and medication treatments for ADHD: Comparisons and combinations. Consensus Conference on the Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder, Bethesda, National Institutes of Health.
43. Jensen, P.S., Bhatara, V.S., Vitiello, B., Hoagwood, K., Feil, M., & Burke, L.B. (1999). Psychoactive medication prescribing practices for U.S. children: Gaps between research and clinical practice. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 557-565.
44. Jensen, P.S., Kettle, L., Roper, M.T., Sloan, M.T., Dulcan, M.K., Hoven, C., Bird, H.R., Bauermeister, J.J., & Payne, J.D. (1999). Are stimulants over prescribed? Treatment of ADHD in four communities. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 797-804.
45. Kavale, K. (1982). The efficacy of stimulant drug treatment for hyperactivity: A meta-analysis. Journal of Learning Disabilities, 15, 280.
46. Klein, R.G., Landa, B., Mattes, J.A., & Klein, D.F. (1988). Methylphenidate and growth in hyperactive children: A controlled withdrawal study. Archives of General Psychiatry, 45, 1127-1130.
47. Kuhn, R. (1958). The treatment of depressive states with G 22355 (imipramine hydrochloride). American Journal of Psychiatry, 115, 459.
48. Laufer, M., & Denhoff, E. (1957). Hyperkinetic behavior syndrome in children. Journal of Pediatrics, 50, 463-474.
49. Mandoki, M. (1995). Effect of venlafaxine on major depression in children and adolescents. Scientific Proceedings of the American Academy of Child and Adolescent Psychiatry XI.
50. Mannuzza, S., Klein, R.G., Bonagura, N., Malloy, P., Giampino, T.L., & Addalli, K.A. (1991). Hyperactive boys almost grown up, V: Replication of psychiatric status. Archives of General Psychiatry, 48, 77-83.
51. March, J.S., Biederman, J., Wolkow, R., Safferman, A., Mardekian, J., Cook, E.H., Cutler, N.R., Dominguez, R., Fergusson, J., Muller, B., Riesenberg, R., Rosenthal, M., Sallee, F.R., Wagner, K.D., & Steiner, H. (1998). Sertraline in children and adolescents with obsessive-compulsive disorder: A multi-center randomized controlled trial. Journal of the American Medical Association, 280, 1752-1756.
52. McDougle, C.J., Holmes, J.P., Bronson, M.R., Anderson, G.M., Volkmar, F.R., Price, L.H., & Cohen, D.J. (1997). Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 685-693.
53. McGinnis, J. (1997). Attention deficit disaster. The Wall Street Journal, p. A14.
54. McKnew, D.H., Cytryn, L., Buchsbaum, M.S., Hamovit, J., Lamour, M., Rapoport, J.L., & Gershon, E.S. (1981). Lithium in children of lithium-responding parents. Psychiatry Research, 4, 171-180.
55. Mikkelson, E.J., Detlor, J., & Cohen, D.J. (1981). School avoidance and social phobia triggered by haloperidol in patients with Tourette's disorder. American Journal of Psychiatry, 138, 1572-1576.
56. Miller, A., Lee, S.K., Raina, P., Klassen, A., Zupanic, J., & Olsen, L. (1998). A Review of Therapies for Attention Deficit/Hyperactivity Disorder. Vancouver: Research Institute for Children's and Women's Health and University of British Columbia.
57. Moffatt, M.E. (1997). Nocturnal enuresis: A review of the efficacy of treatments and practical advice for clinicians. Journal of Developmental and Behavioral Pediatrics, 18, 49-56.
58. Molitch, M., & Eccles, A.K. (1937). Effect of benzedrine sulphate on intelligence scores of children. American Journal of Psychiatry, 94, 587-590.
59. Naruse, H., Nagahata, M., Nakane, Y., Shirahashi, K., Takesada, M., & Yamazaki, K. (1982). A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatric, 48, 173-184.
60. Ottenbacher, K.J., & Cooper, H.M. (1983). Drug treatment of hyperactivity in children. Developmental Medicine and Child Neurology, 25, 358-366.
61. Papatheodorou, G., & Kutcher, S.P. (1993). Divalproex sodium treatment in late adolescent and young adult mania. Psychopharmcology Bulletin, 29, 213-219.
62. Perry, R., Pataki, C., Munoz-Silva, D.M., Armenteros, J., & Silva, R.R. (1997). Risperidone in children and adolescents with pervasive developmental disorder: Pilot trial and follow-up. Journal of Child and Adolescent Psychopharmacology, 7, 167-179.
63. Pool, D., Bloom, W., Mielke, D.H., Roniger, J.J. Jr, & Gallant, D.M. (1976). A controlled evaluation of Loxitane in seventy-five adolescent schizophrenic patients. Current Therapy Research, 19, 99-104.
64. Post, R.M., Ketter, T.A., Denicoff, K., Pazzaglia, P.J., Leverich, G.S., Marangell, L.B., Callahan, A.M., George, M.S., & Frye, M.A. (1996). The place of anticonvulsant therapy in bipolar illness. Psychopharmacology, 128, 115-129.
65. Purdon, S.E., Lit, W., Labelle, A., & Jones, B.D. (1994). Risperidone in the treatment of pervasive developmental disorder. Canadian Journal of Psychiatry, 39, 400-405.
66. Quinn, P.O., & Rapoport, J.L. (1975). One-year follow-up of hyperactive boys treated with imipramine or methylphenidate. American Journal of Psychiatry, 132, 241-245.
67. Rapoport, J.L., Quinn, P.O., Bradbard, G., Riddle, K.D., & Brooks, E. (1974). Imipramine and methylphenidate treatments of hyperactive boys: A double-blind comparison. Archives of General Psychiatry, 30, 789-793.
68. Rapoport, J.L., Buchsbaum, M.S., Zahn, T.P., Weingartner, H., Ludlow, C., & Mikkelsen, E.J. (1978). Dextroamphetamine: Cognitive and behavioral effects in normal prepubertal boys. Science, 199, 560-563.
69. Rappley, M.D., Gardiner, J.C., Jetton, J.R., & Houang, R.T. (1995). The use of methylphenidate in Michigan. Archives of Pediatric and Adolescent Medicine, 149, 675-679.
70. Riddle, M.A., Reeve, E.A., Yaryura-Tobias, J.A., Yang, H.M., Claghorn, J.L., Gaffney, G., Greist, J.H., Holland, D., McConville, B.J., Pigott, T., & Walkup, J.T. (2001). Fluvoxamine for children and adolescents with obsessive-compulsive disorder: A randomized, controlled, multi-center trial. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 222-229.
71. Ruel, J.M., & Hickey, C.P. (1992). Are too many children being treated with methylphenidate? Canadian Journal of Psychiatry, 37, 570-572.
72. Rushton, J.L., Clark, S.J., & Freed, G.L. (2000a). Pediatrician and family physician prescription of selective seratonin reuptake inhibitors. Pediatrics, 105, e82.
73. Rushton, J.L., Clark, S.J., & Freed, G.L. (2000b). Primary care role in the management of childhood depression: A comparison of pediatricians and family physicians. Pediatrics, 105, 957-962.
74. Ryan, N.D., Bhatara, V.S., & Perel, J.M. (1999). Mood stabilizers in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 529-536.
75. Safer, D.J., & Krager, J.M. (1988). A survey of medication treatment for hyperactive/inattentive students. Journal of the American Medical Association, 260, 2256-2258.
76. Safer, D.J., & Krager, J.M. (1992). Effect of a media blitz and a threatened lawsuit on stimulant treatment. Journal of the American Medical Association, 268, 1004-1007.
77. Safer, D.J., Zito, J.M., & Fine, E.M. (1996). Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics, 98, 1084-88.
78. Sallee, F.R., Nesbitt, L., Jackson, C., Sine, L., & Sethuraman, G. (1997). Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. American Journal of Psychiatry, 154, 1057-1062.
79. Shapiro, A.K., & Shapiro, E. (1984). Controlled study of pimozide v. placebo in Tourette's syndrome. Journal of the American Academy of Child Psychiatry, 23, 161-173.
80. Shapiro, E., Shapiro, A.K., Fulop, G., Hubbard, M., Mandeli, J., Nordlie, J., & Phillips, R.A. (1989). Controlled study of haloperidol, pimozide, and placebo for the treatment of Giles de la Tourette's syndrome. Archives of General Psychiatry, 46, 722-730.
81. Sherman, M., & Hertzig, M.E. (1991). Prescribing practices of Ritalin: The Suffolk County, New York study. In L. Greenhill & B. Osman (Eds.), Ritalin Theory and Patient Management. New York: M.A. Liebert.
82. Simeon, J., Dinicola, V.F., Ferguson, H.B., & Copping, W. (1990). Adolescent depression: A placebo-controlled fluoxetine study and follow-up. Progress in Neuropsychopharmacology and Biological Psychiatry, 14, 791-795.
83. Simeon, J., Ferguson, H.B., Knott, V., Roberts, N., Gauthier, B., Dubois, C., & Wiggins, D. (1992). Clinical, cognitive and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 29-33.
84. Solanto, M. (1998). Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: A review and integration. Behavior and Brain Research, 94, 127-152.
85. Spencer, E., Kafantaris, V., Padron-Gayol, M.V., Rosenberg, C.R., & Campbell, M. (1992). Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacology Bulletin, 28, 183-186.
86. Spencer, T., Biederman, J., Wilens, T., Harding, M., O'Donnell, D., & Griffin, S. (1996). Pharmacotherapy of attention deficit hyperactivity disorder across the life span. Journal of American Academy of Child and Adolescent Psychiatry, 35, 409-432.
87. Stuppaeck, C., Barnas, C., Miller, C., Schwitzer, J., & Fleischhacker, W.W. (1990). Carbamazepine in the prophylaxis of mood disorders. Journal of Clinical Psychopharmacology, 10, 39-42.
88. Swanson, J.M., McBurnett, K., Wigal, T., Pfiffner, L.J., Lerner, M.A., et al. (1993). Effect of stimulant medication on children with ADD: A review of reviews. Exceptional Children, 60, 154-162.
89. Thurber, S., & Walker, C.E. (1983). Medication and hyperactivity: A meta-analysis. Journal of General Psychology, 108, 79-86.
90. Varley, C., & McClellan, J. (1997). Case study: Additional sudden deaths with tricyclic antidepressants. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 390-394.
91. Volkow, N.D., Wang, G.J., Fowler, J.S., Gatley, S.J., Logan, J., Ding, Y.S., Hitzemann, R., & Pappas, N. (1998). Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. American Journal of Psychiatry, 155, 1325-1331.
92. Weisz, J., & Jensen, P.S. (1999). Efficacy and effectiveness of child and adolescent psychotherapy and psychopharmacology. Mental Health Services Research, 1, 125-157.
93. Werry, J., Aman, M.G., & Diamond, E. (1979). Imipramine and methylphenidate in hyperactive children. Journal of Child Psychology and Psychiatry, 21, 27-35.
94. West, S., Keck, P.E., McElroy, S.L., et al. (1994). Open trial of valproate in the treatment of adolescent mania. Journal of Child and Adolescent Psychopharmacology, 4, 263-267.
95. West, S., Keck, P.E.J., & McElroy, S.L. (1995). Oral loading doses in the valproate treatment of adolescent with mixed bipolar disorder. Journal of Child and Adolescent Psychopharmacology, 5, 225-231.
96. Winsberg, B., Bialer, I., Kupietz, K.S., & Tobias, J. (1972). Effects of imipramine and dextroamphetamine on behavior of neuropsychiatrically impaired children. American Journal of Psychiatry, 128, 1425-1431.
97. Wolraich, M.L., Lindgren, S., Stromquist, A., Milich, R., Davis, C., & Watson, D. (1990). Stimulant medication use by primary care physicians in the treatment of attention deficit hyperactivity disorder. Pediatrics, 86, 95-101.
98. Yepes, L., Balka, E.B., Winsberg, B.G., & Bialer, I. (1977). Amitriptyline and methylphenidate treatment of behavioral disordered children. Journal of Child Psychology and Psychiatry, 18, 39-52.
99. Zarin, D., Suarez, A.P., Pincus, H.A., Kupersanin, E., & Zito, J.M. (1998). Clinical and treatment characteristics of children with attention-deficit/hyperactivity disorder (ADHD) in psychiatric practice. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 1262-1270.
100. Zito, J., Safer, D.J., DosReis, S., Gardner, J.F., Boyles, M., & Lynch, F. (2000). Trends in the prescribing of psychotropic medication to preschoolers. Journal of the American Medical Association, 283, 1025-1030.